BPC-157 / TB-500 Compounded

This compounded blend pairs BPC-157 with TB-500 in a single vial. It's typically chosen when a clinician wants both repair-signaling peptides in one protocol.

BPC-157 is studied for tissue-repair signaling; TB-500 is a fragment related to thymosin beta-4, studied for cell migration and flexibility of connective tissue. Human evidence for both is limited.

• Active adults in a dedicated recovery block
• People whose clinician recommends combined soft-tissue and connective-tissue support

Subcutaneous injection from a single combined vial across a 28-, 56-, or 84-day cycle as directed.

Most protocols run the full cycle before reassessment. Individual results vary and are not guaranteed.

• Human clinical evidence is limited for both peptides.
• Disclose any history of cancer or active malignancy during intake.
• Injection-site reactions and short-lived fatigue are the most common reports.
• Share your full medication list, medical history, and any allergies during intake.
• Not for use if you are pregnant, planning pregnancy, or breastfeeding unless your clinician says otherwise.
• Stop use and contact your clinician or seek medical care if you experience an unexpected or severe reaction.

Is this FDA-approved?

This is a compounded medication prepared by a licensed US pharmacy for an individual patient. Compounded preparations are not FDA-approved products and are only dispensed after a licensed clinician reviews your intake and determines the therapy is appropriate for you.

Why the combination?

Some clinicians prefer covering both repair pathways in one vial for simplicity and adherence.